

2-20-03

1648
#15
ML

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

Date of Mailing: February 19, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service, addressed to Commissioner for Patents, Washington, DC 20231 and mailed on the above Date of Mailing.

Helena Beckman
Helena Beckman

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|--|---|---------------------------|
| In re Application |) | <u>PATENT APPLICATION</u> |
| |) | |
| Inventor(s): Laquerre et al. |) | |
| |) | Art Unit 1648 |
| SC/Serial No.: 09/741,127 |) | |
| |) | Examiner: Mosher, Mary |
| Filed: December 18, 2000 |) | |
| |) | Confirmation No. 6396 |
| Title: Herpes Simplex Virus-1 Glycoprotein |) | |
| Mutants for Treating Unwanted |) | |
| Hyperproliferative Cell Growth |) | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56.

Enclosed with this statement are the following:

[X] Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.

[X] A copy of each cited document as required by 37 C.F.R. §1.98. Copies are not submitted of U.S. applications, 37 C.F.R. §1.98(a)(2)(iii), and copies are not submitted of documents already cited or submitted in a parent application from which benefit under 35

U.S.C. §120 is claimed, 37 C.F.R. §1.98(d). If any of the cited/submitted documents is in a foreign language, a concise explanation of relevancy is provided pursuant to 37 C.F.R. §1.98(a)(3). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. 57 F.R. 2021 (1/17/92). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement. 37 C.F.R. §1.98(c).

This statement should be considered because:

RECEIVED

[X] This statement qualifies under 37 C.F.R. §1.97, subsection (c) because:

FEB 24 2003

TECH CENTER 1600/2900

- 1) It is being filed before the mailing date of a FINAL Office Action and before a Notice of Allowance (whichever occurs first)


--AND (check at least one of the following)--

[X] 1) It is accompanied by the \$240 fee set forth in 37 C.F.R. §1.17(p); or

[X] Fee Authorization. The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615, including any fee for extension of time, which may be required. A duplicate copy of this authorization is enclosed

Respectfully submitted,

Date: February 19, 2003

By: 
Gregory Glotta
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 262-8710